Literature DB >> 20959661

Intratumoral expression level of epidermal growth factor receptor and cytokeratin 5/6 is significantly associated with nodal and distant metastases in patients with basal-like triple-negative breast carcinoma.

Lisa M Sutton1, Jeong S Han, Kyle H Molberg, Venetia R Sarode, Dengfeng Cao, Dinesh Rakheja, Joseph Sailors, Yan Peng.   

Abstract

Triple-negative (TN) breast carcinoma, characterized by estrogen receptor, progesterone receptor, and HER2 negativity, is a group of aggressive tumors that can be further classified into 2 subtypes: basal-like, defined as CK5/6 and/or epidermal growth factor receptor (EGFR) positive by immunohistochemistry; and non-basal-like. Clinical characteristics and tumor profiles were analyzed in 105 cases of TN tumors. Among these cases, 35 had distant metastasis, 34 had axillary nodal metastasis only, and 36 were nodal negative. Our results indicate basal-like TN breast tumors with nodal and distant metastases are significantly associated with a higher intratumoral expression of EGFR and CK5/6 compared to those in the nodal negative group. High level of intratumoral EGFR and CK5/6 expression may play a role in development of nodal or distant metastases in patients with basal-like TN tumors and may be predictive of metastatic disease. Furthermore, EGFR targeted therapy may be potentially useful in the treatment of basal-like TN breast cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20959661     DOI: 10.1309/AJCPRMD3ARUO5WPN

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  22 in total

1.  Varying outcomes of triple-negative breast cancer in different age groups-prognostic value of clinical features and proliferation.

Authors:  H Vihervuori; K Korpinen; T A Autere; H Repo; K Talvinen; P Kronqvist
Journal:  Breast Cancer Res Treat       Date:  2022-10-19       Impact factor: 4.624

2.  N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy.

Authors:  Jennifer A Crozier; Pooja P Advani; Betsy LaPlant; Timothy Hobday; Anthony J Jaslowski; Alvaro Moreno-Aspitia; Edith A Perez
Journal:  Clin Breast Cancer       Date:  2015-08-19       Impact factor: 3.225

3.  Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR.

Authors:  Daniela A Ferraro; Nadège Gaborit; Ruth Maron; Hadas Cohen-Dvashi; Ziv Porat; Fresia Pareja; Sara Lavi; Moshit Lindzen; Nir Ben-Chetrit; Michael Sela; Yosef Yarden
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-14       Impact factor: 11.205

4.  Accurate assessment of HER2 gene status for invasive component of breast cancer by combination of immunohistochemistry and chromogenic In Situ hybridization.

Authors:  Xiu Nie; Jun He; Yan Li; Dan-Zhen Pan; Hua-Xiong Pan; Mi-Xia Weng; Xiu-Ping Yang; Chun-Ping Liu; Tao Huang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-06-17

5.  Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.

Authors:  Ashley M Brinkman; Guojun Chen; Yidan Wang; Curtis J Hedman; Nathan M Sherer; Thomas C Havighurst; Shaoqin Gong; Wei Xu
Journal:  Biomaterials       Date:  2016-05-27       Impact factor: 12.479

6.  Expression and Clinical Significance of Claudin-7, PDL-1, PTEN, c-Kit, c-Met, c-Myc, ALK, CK5/6, CK17, p53, EGFR, Ki67, p63 in Triple-negative Breast Cancer-A Single Centre Prospective Observational Study.

Authors:  Chloe Constantinou; Savvas Papadopoulos; Eirini Karyda; Athanasios Alexopoulos; Niki Agnanti; Anna Batistatou; Haris Harisis
Journal:  In Vivo       Date:  2018 Mar-Apr       Impact factor: 2.155

7.  Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer.

Authors:  Luciana P Schwab; Danielle L Peacock; Debeshi Majumdar; Jesse F Ingels; Laura C Jensen; Keisha D Smith; Richard C Cushing; Tiffany N Seagroves
Journal:  Breast Cancer Res       Date:  2012-01-07       Impact factor: 6.466

8.  Epidermal growth factor receptor and AKT1 gene copy numbers by multi-gene fluorescence in situ hybridization impact on prognosis in breast cancer.

Authors:  Jiao Li; Wei Su; Sheng Zhang; Yunhui Hu; Jingjing Liu; Xiaobei Zhang; Jingchao Bai; Weiping Yuan; Linping Hu; Tao Cheng; Anders Zetterberg; Zhenmin Lei; Jin Zhang
Journal:  Cancer Sci       Date:  2015-03-16       Impact factor: 6.716

9.  Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options.

Authors:  Pierluigi Gasparini; Matteo Fassan; Luciano Cascione; Gulnur Guler; Serdar Balci; Cigdem Irkkan; Carolyn Paisie; Francesca Lovat; Carl Morrison; Jianying Zhang; Aldo Scarpa; Carlo M Croce; Charles L Shapiro; Kay Huebner
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

10.  Immunophenotypes of glycogen rich clear cell carcinoma.

Authors:  Sung Eun Kim; Ja Seung Koo; Woo-Hee Jung
Journal:  Yonsei Med J       Date:  2012-11-01       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.